BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27246982)

  • 21. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
    Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
    Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.
    Hilton HN; Patterson McDonald LJ; Santucci N; van der Bent FR; Silvestri A; Graham JD; Clarke CL
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):257-270. PubMed ID: 31104199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
    Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
    Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.
    Courtin A; Communal L; Vilasco M; Cimino D; Mourra N; de Bortoli M; Taverna D; Faussat AM; Chaouat M; Forgez P; Gompel A
    Breast Cancer Res Treat; 2012 Jan; 131(1):49-63. PubMed ID: 21336598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-estrogenic mechanism of unliganded progesterone receptor isoform B in breast cancer cells.
    Zheng ZY; Zheng SM; Bay BH; Aw SE; C-L Lin V
    Breast Cancer Res Treat; 2008 Jul; 110(1):111-25. PubMed ID: 17687644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of
    Sau A; Cabrita MA; Pratt MAC
    Cancer Prev Res (Phila); 2018 Feb; 11(2):69-80. PubMed ID: 29101208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.
    Ansquer Y; Legrand A; Bringuier AF; Vadrot N; Lardeux B; Mandelbrot L; Feldmann G
    Anticancer Res; 2005; 25(1A):243-8. PubMed ID: 15816544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
    Bramley M; Clarke RB; Howell A; Evans DG; Armer T; Baildam AD; Anderson E
    Br J Cancer; 2006 Apr; 94(7):1021-8. PubMed ID: 16538216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of BRCA1 gene mutations in patients with early-onset breast cancer and their affected relatives in Guangdong province].
    Zhou J; Rao NY; Li SR; Jin L; Jia WJ; Gong C; Yu FY; Su FX; Song EW; Shao ZM
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb; 29(2):213-6. PubMed ID: 19246281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
    Ashraf M; Jha JK; Mukherjee N; Panda CK; Nayak S; Jadhav TS; Dikshit N; Nath NC; Chakraborty J; Biswas J
    J Indian Med Assoc; 2011 Dec; 109(12):873-8. PubMed ID: 23469566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting progesterone signaling prevents metastatic ovarian cancer.
    Kim O; Park EY; Kwon SY; Shin S; Emerson RE; Shin YH; DeMayo FJ; Lydon JP; Coffey DM; Hawkins SM; Quilliam LA; Cheon DJ; Fernández FM; Nephew KP; Karpf AR; Widschwendter M; Sood AK; Bast RC; Godwin AK; Miller KD; Cho CH; Kim J
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):31993-32004. PubMed ID: 33262282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
    Zheng L; Annab LA; Afshari CA; Lee WH; Boyer TG
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9587-92. PubMed ID: 11493692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
    Tung N; Wang Y; Collins LC; Kaplan J; Li H; Gelman R; Comander AH; Gallagher B; Fetten K; Krag K; Stoeckert KA; Legare RD; Sgroi D; Ryan PD; Garber JE; Schnitt SJ
    Breast Cancer Res; 2010; 12(1):R12. PubMed ID: 20149218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
    Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
    Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.